Atreca Inc BCEL

Alternate Symbol(s): COLUF

Atreca, Inc. is a clinical-stage biopharmaceutical company. The Company is discovering and developing antibody-based therapeutics to treat a range of solid tumor types. Its most advanced product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. It commenced clinical development of ATRC-101 with a Phase Ib clinical trial evaluating ATRC-101 as a monotherapy in patients with select solid tumors and opens a new cohort to evaluate ATRC-101 in combination with pembrolizumab, a PD-1 checkpoint inhibitor. It is also advancing additional product candidates using its discovery platform. Its oncology programs include APN-497444, an ADC against a tumor glycan target, and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target.

PINL:BCEL - Post by User

Atreca Inc

Bullboard Posts

Post by TheHoboon Mar 11, 2010 11:07am

277 Views

Post# 16870712

L2 Data @ 11:07 eastern

Orders/Shares    Price    Price    Shares/Orders
6 / 2700   5.83   5.84   200 / 1
1 / 1000   5.81   5.85   5100 / 2
2 / 4000   5.8   5.86   100 / 1
1 / 800       5.79   5.87   4100 / 3
2 / 3000   5.78   5.88   9300 / 5
1 / 500       5.75   5.89   3500 / 2
1 / 1700   5.74   5.9   8000 / 4
4 / 3100   5.71   5.92   10500 / 2
2 / 1300   5.7   5.93   15000 / 2
1 / 2000   5.69   5.94   2500 / 2
1 / 500       5.68   5.95   20400 / 9
1 / 1000   5.67   5.97   1000 / 1
1 / 1000   5.65   5.99   5000 / 4
2 / 2800   5.61   6   19000 / 9
3 / 6500   5.6   6.05   1700 / 1
1 / 5000   5.59   6.07   2500 / 1
1 / 1000   5.54   6.09   5000 / 1
1 / 500       5.52   6.1   200 / 1
3 / 3800   5.51   6.15   100 / 1
2 / 1300   5.5   6.19   11000 / 3

Bullboard Posts

Amazon stock reaches for record highs after earnings report